Evidence map›Paper›PMID 32021879›Full record

ArticleMolecular therapy. Methods & clinical development2020

CRISPR-Cpf1 Activation of Endogenous

Jaehoon Choi, Taegeun Bae, Ninj Byambasuren, Seong-Ho Park, Chris H Jo, Dokyoung Kim, Junho K Hur, Nathaniel S Hwang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Recent application of CRISPR-Cas12 and OMEGA system for genome editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Umbilical cord mesenchymal stromal cells-from bench to bedside.Frontiers in cell and developmental biology · 2022
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jaehoon ChoiSchool of Chemical and Biological Engineering, Institute of Chemical Processes, Seoul National University, Seoul, Korea.
Taegeun BaeDepartment of Medicine, Graduate School, Kyung Hee University, Seoul, Korea.
Ninj ByambasurenInterdisciplinary Program in Bioengineering, Institute of Bio Engineering, Seoul National University, Seoul, Korea.
Seong-Ho ParkDepartment of Biomedical Science, Graduate School, Kyung Hee University, Seoul, Korea.
Chris H JoDepartment of Orthopedic Surgery, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Dokyoung KimDepartment of Anatomy and Neurobiology, College of Medicine, Kyung Hee University, Seoul, Korea.
Junho K HurDepartment of Biomedical Science, Graduate School, Kyung Hee University, Seoul, Korea.
Nathaniel S HwangSchool of Chemical and Biological Engineering, Institute of Chemical Processes, Seoul National University, Seoul, Korea.
Kyung Hee University · KRSeoul National University · KRSNUH SMG-SNU Boramae Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CRISPR systems provide powerful genome-editing tools for wide applications in biological and medical research fields. However, the safety issue due to off-target effects of CRISPR has been one of the major hindrances of its application to regenerative medicine. The conventional CRISPR system has the intrinsic danger of inducing unpredictable mutations at non-targeted genomic loci via erroneous double-strand DNA breaks (DSBs). In this study, we demonstrate a safety-enhanced application of a recently discovered CRISPR-Cpf1 for targeted gene activation, without DNA double-strand break, to facilitate osteogenic differentiation of human umbilical-cord-derived mesenchymal stem cells (UC-MSCs). To this end, we developed a catalytically inactive AsCpf1 fused to tripartite transcription activator domain (dAsCpf1-VPR) that can induce upregulation of targeted gene expression in mammalian cells. We observed that the CRISPR-dAsCpf1-VPR activator can be applied to enhance the osteogenic differentiation of human UC-MSCs, via increasing the expression level of endogenous

Indexed as

Cell DifferentiationCell EngineeringCpf1CRISPR activationCRISRPMesenchymal Stem Cell

Identifiers

PMID32021879
PMCPMC6994413
OpenAlexW2999455045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.